

# Rainer Kimmig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7716254/publications.pdf>

Version: 2024-02-01

115  
papers

5,148  
citations

201674

27  
h-index

88630

70  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7034  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	27.0	1,843
2	Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R46.	5.0	658
3	Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. <i>Breast Cancer Research</i> , 2012, 14, R15.	5.0	262
4	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. <i>Breast Cancer Research</i> , 2009, 11, R59.	5.0	217
5	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	2.5	105
6	ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance. <i>Clinical Chemistry</i> , 2014, 60, 1282-1289.	3.2	101
7	Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS). <i>Journal of Gynecologic Oncology</i> , 2020, 31, e59.	2.2	97
8	Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1072-1076.	2.5	92
9	Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. <i>Oncolmmunology</i> , 2018, 7, e1376153.	4.6	86
10	LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5500-5500.	1.6	81
11	The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. <i>Human Immunology</i> , 2016, 77, 791-799.	2.4	77
12	Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. <i>Breast Cancer Research</i> , 2016, 18, 20.	5.0	72
13	EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. <i>Oncotarget</i> , 2017, 8, 48820-48831.	1.8	72
14	RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1054-1062.	3.2	55
15	Minimally invasive surgery for cervical cancer: consequences for treatment after LACC Study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e75.	2.2	49
16	Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1316-1326.	10.7	39
17	ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 24303-24313.	1.8	38
18	Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. <i>BMC Cancer</i> , 2019, 19, 120.	2.6	37

#	ARTICLE	IF	CITATIONS
19	Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 3730-3737.	1.5	36
20	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 0, 7, 41677-41690.	1.8	36
21	Risk-reducing, conservative mastectomy-analysis of surgical outcome and quality of life in 272 implant-based reconstructions using TiLoop(A®) Bra versus autologous corial flaps. <i>Gland Surgery</i> , 2016, 5, 1-8.	1.1	36
22	Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 30.	3.3	34
23	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	3.2	34
24	Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanineâ€green (ICG). <i>Journal of Surgical Oncology</i> , 2016, 113, 554-559.	1.7	31
25	Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 497-509.	5.4	31
26	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) â€“ Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1089-1109.	1.8	30
27	Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1106.	3.7	30
28	Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. <i>Clinical Imaging</i> , 2018, 49, 163-168.	1.5	29
29	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1369-1378.	7.0	28
30	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
31	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. <i>Cancers</i> , 2019, 11, 238.	3.7	26
32	Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as â€total mesometrial resection (TMMR)â€™ by M HÄ¶ckel translated to robotic surgery (rTMMR). <i>World Journal of Surgical Oncology</i> , 2013, 11, 211.	1.9	25
33	Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M HÄ¶ckel translated to robotic surgery. <i>World Journal of Surgical Oncology</i> , 2013, 11, 198.	1.9	25
34	Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?. <i>Scientific Reports</i> , 2016, 6, 26355.	3.3	25
35	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4693.	4.1	25
36	Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. <i>Anticancer Research</i> , 2011, 31, 3623-8.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Human sFLT1 Leads to Severe Changes in Placental Differentiation and Vascularization in a Transgenic hsFLT1/rtTA FGR Mouse Model. <i>Frontiers in Endocrinology</i> , 2019, 10, 165.	3.5	24
38	Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. <i>Cells</i> , 2021, 10, 212.	4.1	24
39	Breast conservative surgery and local recurrence. <i>Breast</i> , 2015, 24, S100-S107.	2.2	23
40	B3-lesions of the breast and cancer risk - an analysis of mammography screening patients. <i>Molecular and Clinical Oncology</i> , 2016, 4, 705-708.	1.0	22
41	Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2012, 13, 12000-12016.	4.1	21
42	Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 85.	8.2	21
43	Definition of Compartment Based Radical Surgery in Uterine Cancer Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael HÄ¶ckel Translated to Robotic Surgery. <i>ISRN Obstetrics &amp; Gynecology</i> , 2013, 2013, 1-17.	1.2	20
44	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2233-2238.	2.5	20
45	Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 153-160.	1.7	19
46	Afamin: an early predictor of preeclampsia. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 1009-1016.	1.7	18
47	HLA-G 3â€™ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5407.	3.3	18
48	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 670-683.	2.5	18
49	Combinatorial Power of cfDNA, CTCs and EVs in Oncology. <i>Diagnostics</i> , 2022, 12, 870.	2.6	18
50	Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1658.	2.8	17
51	Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 1084.	3.7	17
52	Zinc distribution within breast cancer tissue of different intrinsic subtypes. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 195-205.	1.7	17
53	Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. <i>Journal of Chemotherapy</i> , 2016, 28, 210-217.	1.5	15
54	High serum levels of periostin are associated with a poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 515-524.	2.5	15

#	ARTICLE	IF	CITATIONS
55	CCN3 Signaling Is Differently Regulated in Placental Diseases Preeclampsia and Abnormally Invasive Placenta. <i>Frontiers in Endocrinology</i> , 2020, 11, 597549.	3.5	14
56	Technique of ICG-guided Targeted Compartmental Pelvic Lymphadenectomy (TCL) combined with Pelvic Peritoneal Mesometrial Resection (PMMR) for locoregional control of endometrial cancer – A proposal. <i>Gynecologic Oncology Reports</i> , 2017, 20, 125-126.	0.6	13
57	Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8405-8416.	3.6	13
58	Changes in the Blood Serum Levels of the Costimulatory Soluble B7-4 Molecule in Pregnant Women During the Peripartal Phase. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 209-215.	1.2	12
59	Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally. <i>Endocrine Connections</i> , 2019, 8, 616-624.	1.9	12
60	Serum concentrations of soluble B7-4 in early pregnancy are elevated in women with preterm premature rupture of fetal membranes. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 149-154.	1.2	11
61	Early ovarian cancer surgery with indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, pelvic part). <i>Journal of Gynecologic Oncology</i> , 2017, 28, e68.	2.2	11
62	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	1.4	11
63	Association of the AA genotype of the BCL2 (rs938) promoter polymorphism with better survival in ovarian cancer. <i>International Journal of Biological Markers</i> , 2009, 24, 223-229.	1.8	10
64	The haplotype of three polymorphisms in the SATB1 promoter-region and impact on survival in breast cancer patients. <i>Journal of Clinical Oncology</i> , 2013, 31, 584-584.	1.6	10
65	Surgical treatment of early ovarian cancer with compartmental resection of regional lymphatic network and indocyanine-green-guided targeted compartmental lymphadenectomy (TCL, paraaortic) Tj ETQq1 1 0.284314 rgBT /Overlo		
66	Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 949-971.	1.8	9
67	Follistatin during pregnancy and its potential role as an ovarian suppressing agent. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 212, 150-154.	1.1	8
68	Cancer field surgery in endometrial cancer: peritoneal mesometrial resection and targeted compartmental lymphadenectomy for locoregional control. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e7.	2.2	8
69	Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 5479-84.	1.1	8
70	Soluble CEACAM1 and CEACAM6 are differently expressed in blood serum of pregnant women during normal pregnancy. <i>American Journal of Reproductive Immunology</i> , 2017, 78, e12700.	1.2	7
71	Total mesometrial resection (TMMR) for cervical cancer FIGO IB-IIA: first results from the multicentric TMMR register study. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e9.	2.2	7
72	Systematic Evaluation of HLA-G Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome. <i>Frontiers in Immunology</i> , 2021, 12, 817132.	4.8	7

#	ARTICLE	IF	CITATIONS
73	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1139-1148.	2.4	6
74	Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic system. <i>Gynecologic Oncology Reports</i> , 2016, 16, 24.	0.6	6
75	Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1159-1174.	2.5	6
76	Multimodality in liquid biopsy: does a combination uncover insights undetectable in individual blood analyses?. <i>Laboratoriums Medizin</i> , 2022, 46, 255-264.	0.6	6
77	Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines. <i>BMC Cancer</i> , 2012, 12, 451.	2.6	5
78	The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients. <i>Oncology Letters</i> , 2014, 7, 2007-2012.	1.8	5
79	Intraindividual rightâ€“left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 181, 124-129.	1.1	5
80	HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. <i>Pathology and Oncology Research</i> , 2021, 27, 636088.	1.9	5
81	Abnormal expression of the costimulatory molecule B7â€“4 in placental chorionic villous and decidual basalis tissues of patients with preeclampsia and HELLP syndrome. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13430.	1.2	5
82	Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. <i>Modern Pathology</i> , 2004, 17, 15-21.	5.5	5
83	Left paraaortic, inframesenteric lymphadenectomy preserving the superior hypogastric plexus supported by indocyanine green (ICG) labeling of the lymphatic compartment in cervical cancer. <i>Gynecologic Oncology Reports</i> , 2016, 18, 14.	0.6	4
84	Aortic utero-ovarian sentinel nodes and left infrarenal aortic lymph node dissection by ICG supported navigation. <i>Gynecologic Oncology Reports</i> , 2017, 20, 22-23.	0.6	4
85	Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArrayâ„“HER2-FISH workflow. <i>Breast Cancer</i> , 2022, 29, 487-497.	2.9	4
86	Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture. <i>Journal of Reproductive Immunology</i> , 2014, 106, 50-57.	1.9	3
87	Surgical anatomy of the ligamentous mesometrium and robotically assisted ICG-guided resection in cervical cancer. <i>Gynecologic Oncology Reports</i> , 2017, 20, 4.	0.6	3
88	Tight interplay in early pregnancy between follistatin and anti-mullerian hormone in women with polycystic ovarian syndrome (PCOS). <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 1307-1316.	1.7	3
89	The role of sentinel-node biopsy in ovarian cancer. <i>Minerva Ginecologica</i> , 2021, 72, 399-403.	0.8	3
90	Accuracy of Ultrasonography and Magnetic Resonance Imaging for Preoperative Staging of Cervical Cancerâ€“Analysis of Patients from the Prospective Study on Total Mesometrial Resection. <i>Diagnostics</i> , 2021, 11, 1749.	2.6	3

#	ARTICLE	IF	CITATIONS
91	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	3.7	3
92	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
93	Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5550-5550.	1.6	2
94	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5042-5042.	1.6	2
95	In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells. <i>Cancers</i> , 2022, 14, 3299.	3.7	2
96	Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1367-1372.	1.7	1
97	What is the evidence for lymphadenectomy in presumed early ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1-5.	1.7	1
98	Updated results of neoadjuvant chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 149-149.	1.6	1
99	Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22032-e22032.	1.6	1
100	Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5520-5520.	1.6	1
101	Catumaxomab in the Treatment of Malignant Ascites: The Evidence of its Therapeutic Value. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S4954.	0.4	0
102	Robotic-Assisted Radical Hysterectomy as Compartmental Resection According to rTMMR and rPMMR. , 2018, , 921-932.		0
103	Robotically Assisted Therapeutic Pelvic and Paraaortic Lymphadenectomy in Uterine Cancer. , 2018, , 933-945.		0
104	Fetal subdural hematoma, sickle cell disease and storage pool disease: A case report. <i>Case Reports in Women's Health</i> , 2020, 26, e00183.	0.5	0
105	Targeted breast surgery: Non-direct approach.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12602-e12602.	1.6	0
106	Risk-reducing surgery by skin-sparing mastectomy (SSM) and immediate implant-based reconstruction with and without titanized meshes and quality of life.. <i>Journal of Clinical Oncology</i> , 2012, 30, 48-48.	1.6	0
107	Triple-negative breast cancer (TNBC) and residual disease (non-pCR): Does size matter?. <i>Journal of Clinical Oncology</i> , 2012, 30, 106-106.	1.6	0
108	Clinical relevance of VEGF-receptor status in primary ovarian cancer: A pilot study for future biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5556-5556.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. Journal of Clinical Oncology, 2013, 31, 5575-5575.	1.6	0
110	Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrow.. Journal of Clinical Oncology, 2013, 31, e11516-e11516.	1.6	0
111	The FNTB-609G>C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib.. Journal of Clinical Oncology, 2014, 32, e16534-e16534.	1.6	0
112	Single nucleotide polymorphisms of the EpCAM-coding gene <i>TACSTD1</i> in patients with ovarian cancer and their potential implications in clinical practice.. Journal of Clinical Oncology, 2014, 32, e16515-e16515.	1.6	0
113	Compartmental Theory in Uterine Cancer, Anatomical Considerations and Principles of Compartmental Cervical Cancer Surgery Step by Step. , 2018, , 103-115.		0
114	Peritoneal Mesometrial Resection (PMMR) with Therapeutic Lymphadenectomy (tLNE) in Endometrial Cancer. , 2018, , 117-126.		0
115	Sentinel-Lymphnode Biopsy in primary breast cancer: 99mTc versus ICG&A prospective, randomized trial.. Journal of Clinical Oncology, 2020, 38, 575-575.	1.6	0